

**nexus | ag**



# Half-Year Report

01<sup>ST</sup> JANUARY TO 30<sup>TH</sup> OF JUNE 2020

# Letter to Our Shareholders

Dear Shareholders:

The COVID-19 pandemic has been a major concern for us in recent months. As for everyone else, the related challenges were considerable for NEXUS.

Especially in the second quarter, it was very important for us to support our **customers**, hospitals, rehabilitation and nursing homes and to facilitate work with first-class services and customized software adjustments. This applies as it previously did. Now more than ever, we must continue to take care to protect our **employees** and provide them with an environment where they can work safely.

It is a challenge in this phase not to lose sight of our **economic goals**. New ideas, commitment and complete customer focus are needed to cushion the impact of the pandemic on NEXUS. Success is not a matter of course in such a situation. Our customers are also economically affected by the pandemic, and we can only grow successfully if we tailor our software and services to the needs of our customers today.

Until now, the NEXUS team has managed well to tackle these challenges. From an organizational point of view, we adjusted very quickly to the new situation and are available to our **customers with extended service** even more actively than before. We have also succeeded in creating a **safe environment for our employees**. Our offices have sufficient space and other options to comply with the necessary distance and hygiene regulations at all times, and employees with health concerns can work from home if this is possible. It remains important that we do not offset economic considerations against health aspects. We must not compromise in this respect from an entrepreneurial point of view.

Despite these major challenges, we have again succeeded in **achieving significantly increasing key figures in the first half of the year**. This is very good news, which is thanks to the extraordinary commitment of our employees and the trust of our customers.

We have had to deal with **significant regional differences**. While sales in Germany developed very strongly, some national companies were more severely affected by the COVID-19 measures. The comprehensive "lockdown" in Switzerland, Poland and France resulted in stagnating or weaker sales in these national companies. Especially in the services sector, we were not able to be as active as we usually are in these countries due to travel and contact bans. On the product side, our customers in all countries focused on smaller

digitization projects that facilitate work immediately for doctors and nurses. Larger projects on the other hand, which have to be planned in the long term, have been postponed.

Therefore, we are very pleased overall to be able to show a strong increase in sales and earnings in the first half of 2020 and consequently successfully continue our long-term development. Our **sales** increased in the first half of the year compared with the previous year by **approx. 11%**, the result before interest and taxes on income (**EBIT**) increased by **approx. 13%** and the **EBITDA reached approx. €16.7 million** and consequently an **EBITDA margin of approx. 22%**. The operating cash flow amounted to **EUR 261 million** and demonstrates the soundness of our earnings development. As a result, our cash and cash equivalents increased to approx. EUR 51.2 million as of 30 June 2020. The **result per share rose very significantly by 44%** from EUR 0.27 (1st HY 2019) to EUR 0.39.

We are, of course, proud to be able to present such a convincing result in this exceptional period too. However, it has been and continues to be the focus of our efforts to **provide our customers with the best possible support in this difficult situation**. We can only maintain the trust that our customers place in us in the long term in this way.

Especially in recent months, it has been important to focus on providing immediate support to users. These included the provision of new **software applications** dealing with the documentation of COVID-19 cases, the rapid implementation of interfaces for laboratory analyzers, the expansion of our telemedicine product NEXUS / CHILI TKmed, adjustments to billing rules and VAT changes. But this also included completely new solutions such as our NEXUS/LAURIS APP – a complete system for mobile data acquisition during sampling. We also took advantage of the opportunity to provide training sessions, presentations and continued education in the form of webinars, which have been very well received by our customers. We created a comprehensive

## Highlights Half-Year 2020 – Company development

- + Strong sales development in the first half of 2020 thanks to increasing demand for digitalization
- + COVID-19 effects: Regions affected very differently, Germany with a high increase in sales
- + COVID-19 effects: Increasing demand for specific solutions
- + COVID-19 effects: Tenders postponed in part

## Development of Group Sales (6 months) in KEUR

2009–2020



webinar program over the past few weeks that will remain part of our offering after the crisis.

The results of this **product and service initiative** were impressively demonstrated in the second quarter results and also prove that at this stage – more than ever – we can use our **product and technology strength** in the market and react very flexibly to new requirements.

We were able to acquire a large number of new and interesting projects both domestically and abroad in the first half year. This applies in particular to radiology, laboratory and pathology projects as well as to NEXUS / HIS<sup>NG</sup> conversions. Despite this, we saw a **decline in our sales activities** in the second quarter due to contact restrictions. Although some activities could be handled by tele- and video communication, many project awards were postponed until a later date.

In view of the rapidly changing **competitive situation**, however, we also see **great opportunities** in this phase. The numerous acquisitions of competitive products on the German international markets enable us to offer customers of these old products an alternative that puts the advantages of a modern system in the foreground.

Over the past few months, we have focused on expanding our own **product and technology strength** through innovations. We will continue to seek acquisitions from suitable companies, but we will always focus on expanding our product world and not so much on buying market shares. Today, NEXUS is positioned so that we can implement a fully digital hospital with all special applications from our own product portfolio. This is an exceptional position in the market that we can take advantage of in this situation.

## OUTLOOK: BE PREPARED!

Dear shareholders, we have seen a challenging first half of the year and are proud to be able to present you NEXUS in **good shape**. We are not able to **assess the development definitively** of the next few months and have no clear picture yet of how the further measures of the COVID 19 pandemic will affect our business development in the coming months. We therefore have to monitor events very closely and decide on measures in the short term. However, we **are convinced** that our long-term orientation, the high proportion of recurring revenues and our healthy corporate structure make us well prepared for crises.

Consequently, the fact that our **first half-year 2020 has been very successful** is to be considered a very positive development. Both in terms of sales and earnings, we were able to present impressive results and continue the ongoing positive development of recent years.



**Dr. Ingo Behrendt**  
Chief Executive Officer

There is also **reason for optimism** for our future development: Digitization will become an even more important component in society and healthcare, healthcare facilities will increase in importance due to the experiences of the pandemic, and the provision of valid data will become increasingly important for health management: These are all trends that favor NEXUS activities and its business model in the medium and long term.

The accelerated concentration in our industry also provides **additional opportunities for NEXUS**. With our highly differentiated and highly innovative product portfolio, we offer **an attractive alternative to acquired old products**. Customers, who plan to reorient their IT strategy as a result of these acquisitions, can switch to a modern and innovative NEXUS product. We must continue to improve over the next few months and be prepared for these market opportunities.

The NEXUS team is looking forward to these challenges. We want to thank you, dear shareholders, for your trust.

Warm regards,

Dr. Ingo Behrendt  
Chief Executive Officer

## Development of Group Earnings before Interest and Taxes (6 months) in KEUR

2009–2020



# Financial Highlights

## Half-Year 2020 and 2019

	30/06/2020	30/06/2019	Change
SALES AND OPERATING RESULT	KEUR	KEUR	(in %)
Sales	77,659	69,708	11.4
Healthcare Software Sales	73,307	65,673	11.6
Healthcare Service Sales	4,352	4,035	7.9
Domestic sales	43,392	36,183	19.9
Sales in foreign countries	34,267	33,525	2.2
Earnings before taxes (EBT)	8,235	7,261	13.4
Earnings before interest and taxes (EBIT)	8,462	7,488	13.0
EBITA	10,375	9,247	12.2
EBITDA	16,663	15,417	8.1
Consolidated surplus	6,201	5,346	16.0
Cash flow from operating activities	26,081	19,871	31.3
Net income per share (unadjusted / adjusted) in EUR	0.39 / 0.39	0.27 / 0.27	44.4 / 44.4
Share price (closing price, Xetra, in EUR)	39.10	33.20	17.8
Capitalization of software developments	1,398	1,778	-21.4
Depreciation	8,201	7,929	3.4
Acquisition-related depreciations from purchase price allocation	1,913	1,759	8.8
Long-Term Assets	133,495	138,300 <sup>1)</sup>	-3.5
Short-Term Assets	87,521	69,766 <sup>1)</sup>	25.4
Net Liquidity	51,170	36,432	40.5
Equity Capital	116,344	115,135 <sup>1)</sup>	1.1
Employees (Half-Year average)	1,303	1,253	4.0

<sup>1)</sup> Key date 31/12/2019

Due to rounding, there may be slight deviations in the totals and in the calculation of percentages in this report.

# Interim Annual Report

## REPORT ABOUT THE PROFIT, FINANCIAL AND ASSET SITUATION

NEXUS Group sales increased from KEUR 69,708 to KEUR 77,659 (+11.4%) in the first six months of the year 2020. The stable, positive development of NEXUS Group of recent years could be continued with that. We succeed in these matters despite the challenges posed by the COVID-19 pandemic.

Sales increased from KEUR 65,673 (6M 2019) to KEUR 73,307 (+11.6%) in the Healthcare Software Division.

In the Healthcare Service Division, sales of KEUR 4,352 were achieved after KEUR 4,035 (6M 2019), approx. 7.9% more than in the previous year.

We were able to increase sales in Germany by 19.9% to KEUR 43,392 (6M 2019: KEUR 36,183). In international business, we achieved sales of KEUR 34,267 in the first half-year 2020 compared to KEUR 33,525 in the previous year (+2.2%).

The main reasons for this different development are the stagnating or weaker sales caused by the COVID-19 lockdown in Switzerland, Poland and France.

Consolidated earnings before income taxes and interest (EBIT) developed very positively. It improved by 13.0% to KEUR 8,462 (6M 2019: KEUR 7,488). A value of KEUR 10,375 was achieved in EBITA and consequently was 12.2% above the value of previous year (6M 2019: KEUR 9,247). EBITDA reached KEUR 16,663 in the first six months and consequently increased by 8.1% (6M 2019: KEUR 15,417). The result is also burdened by expenses in the context of integrations from acquired companies in the estimated amount of approximately KEUR 1,230.

The cash flow from operating activities increased by 31.3% to a value of KEUR 26,081 (6M 2020: KEUR 19,871) during the reporting period. The main reasons for the strong cash flow in the first half-year were the high incoming payments from the maintenance revenues and reduction of receivables.

The consolidated surplus amounted to KEUR 6,201 for the first half-year 2020 following KEUR 5,346 (6M 2019) and consequently increased by 16.0%. The undiluted result per share amounted to EUR 0.39 (previous year: EUR 0.27) (diluted: EUR 0.39; previous year: EUR 0.27).

Cash and cash equivalents including financial assets amounted to KEUR 51,170 on 30 June 2020 (30 June 2019: KEUR 36,432). The balance sheet total increased from KEUR 208,066 to KEUR 221,016 compared to 31 December 2019. There are no essential bank liabilities. Intangible assets, goodwill and capitalized deferred taxes add up to a total of KEUR 113,886 following previously KEUR 116,345 (31 December 2019). The receivables from customers in the amount of KEUR 24,938 on 30 June 2020 (30 June 2019: KEUR 28,724) decreased due to active receivables management.

### EMPLOYEES

NEXUS Group employed a total average of 1,303 people as of 30 June 2020 (6M-2019: 1,253 employees).


#### EBITDA (6 MONTHS) IN KEUR

+8.1 % in comparison to the previous year



#### EBITA (6 MONTHS) IN KEUR

+12.2 % in comparison to the previous year



## CHANGES IN THE SHAREHOLDING STRUCTURE

The following changes were implemented in the shareholding structure:

- + Nexus AG acquired 100.00% of the shares of AEGERUS S.L., Sabadell (Spain), as of 20 February 2020.
- + Nexus AG acquired a further 5.02% of the shares of the subsidiary NEXUS Polska sp. z o.o., Poznan, on 23 April 2020 from the existing option agreement.
- + With a share purchase agreement dated 30 April 2020, NEXUS Schweiz AG, Altishofen, acquired the remaining 40.00% of the shares in Synergetics AG, Altishofen (Switzerland).
- + Nexus AG acquired a further 6.32% of the shares of the subsidiary NEXUS Polska sp. z o.o., Poznan, on 2 June 2020 from the existing option agreement.
- + Synergetics AG, Altishofen (Switzerland), was merged into NEXUS Schweiz AG, Altishofen (Switzerland) as of 1 January 2020 with a merger agreement dated 16 June 2020.

## EVENTS AFTER THE BALANCE SHEET DATE

NEXUS AG acquired a further 32.54% of the shares of the subsidiary NEXUS / CHILI GmbH, Dossenheim, from the existing option agreement of 7 July 2020.

nexus/cs3i S.A.S, Bellerive-sur-Allier (France) was merged with NEXUS France S.A.S. (formerly NEXUS/OPTIM S.A.S.) on 1 August 2020, Grenoble (France), merged as of 1 March 2020.

## SALES BY REGION

	01/01- 30/06/2020	01/01- 30/06/2019	Change	01/04- 30/06/2020	01/04- 30/06/2019	Change
	KEUR	KEUR	(in %)	KEUR	KEUR	(in %)
Germany	43,392	36,183	19.9	23,201	18,579	24.9
Switzerland / Liechtenstein	16,737	17,675	-5.3	7,271	7,515	-3.3
Netherlands	7,264	7,100	2.3	3,527	3,700	-4.7
Poland	2,441	2,446	-0.2	1,446	1,406	2.8
France	2,989	2,913	2.6	1,444	1,485	-2.8
Austria	1,528	1,707	-10.5	501	1,038	-51.7
Other countries	3,308	1,684	96.4	1,399	520	169.0
TOTAL	77,659	69,708	11.4	38,789	34,243	13.3

## SALES BY DIVISION

	01/01- 30/06/2020	01/01- 30/06/2019	Change	01/04- 30/06/2020	01/04- 30/06/2019	Change
	KEUR	KEUR	(in %)	KEUR	KEUR	(in %)
Healthcare Software	73,307	65,673	11.6	36,570	32,357	13.0
Healthcare Service	4,352	4,035	7.9	2,219	1,886	17.7
TOTAL	77,659	69,708	11.4	38,789	34,243	13.3

### Finance Highlights Half-Year 2020

- + 11.4% sales increase from KEUR 69,708 (1st HY 2019) to KEUR 77,659 in the first half-year 2020
- + 13.0% increase in the Group result before interest and taxes on income (EBIT) from KEUR 7,488 (1st HY 2019) to KEUR 8,462
- + Continued very strong operational cash flow of KEUR 26,081 in the first half-year
- + High net liquidity of KEUR 51,170

## ANNUAL SHAREHOLDERS MEETING AND DIVIDENDS

At the virtual Annual Shareholders Meeting of Nexus AG in Donaueschingen on 30 April 2020, the Executive Board and Supervisory Board proposed to pay a one cent higher dividend of EUR 0.18 to shareholders than the previous year from the net earnings of fiscal year 2019. The proposal was adopted by the required majority. Consequently, there was a total distribution of KEUR 2,835 on 6 May 2020.

# Stock Market, Event and Financial Data

## INVESTOR RELATIONS

Active communication with our shareholders, potential investors, analysts and the finance market are the focal point of our investor relation activities. We continually inform all market participants promptly and comprehensively via press releases and ad hoc announcements as well as the mandatory quarterly, semi-annual and annual financial reports.

In addition, we cultivate intensive dialog with institutional investors and finance analysts via one-on-one meetings and on roadshows. Our Investor Relations team is of course at your disposal as contact persons.

### 11 August 2020

IR Conference Call on  
Half-Year Results

### 02-04 September 2020

Investor Conference HAIB, Stockholm

### 21-23 September 2020

Virtuell Investor Conference Berenberg,  
Munich

### 10 November 2020


Quarterly Statement Q3 / 2020

## Stock Market Highlights until 30/06/2020 (Xetra prices)

- |  |   |
|--|---|
| + Initial listing on<br>02 January 2020: 34.60 € | + Stock market capitalization on<br>30 June 2020: 615.84 Mio. € |
| + Highest price on<br>26 June 2020: 40.40 €      | + Closing price on<br>30 June 2020: 39.10 €                     |

## DEVELOPMENT OF NEXUS STOCK (XETRA PRICES) (1-YEAR PERIOD)





**„Arona is 100% digital. I’ve gotten used to it completely, and I can’t even imagine working with paper in the meantime.“**

**Petra Kretschmer**

Head of Area Division and Nurses,  
ARONA Klinik für Altersmedizin Berlin-Marzahn



**„NEXUS / RIS<sup>NG</sup> is my individual ‘all in one tool’ for optimum quality and the well-being of my patients.“**

**Prof. Dr. Lars Grenacher**

Ärztlicher Direktor und Facharzt für Radiologie,  
Conradia Radiologie München, Curagita AG

# Consolidated Income Statement

**FOR THE PERIOD FROM 01/01/2020 TO 30/06/2020  
AND 01/01/2019 TO 30/06/2019**

	01/01/2020 – 30/06/2020	01/01/2019 – 30/06/2019	01/04/2020-30/06/2020	01/04/2019-30/06/2019
	KEUR	KEUR	KEUR	KEUR
Revenue	77,659	69,708	38,789	34,243
Development work capitalized	1,398	1,778	695	873
Other operating income	5,542	6,996	2,924	4,583
Cost of materials including purchased services	10,823	10,050	5,885	4,825
Personnel costs	47,487	44,465	23,429	22,222
Depreciation	8,201	7,929	4,117	4,263
Other operating expenses	9,626	8,550	4,850	4,783
<b>Operating Result</b>	<b>8,462</b>	<b>7,488</b>	<b>4,127</b>	<b>3,606</b>
Finance income	28	57	0	32
Finance expenses	255	284	97	200
<b>Result before Tax on Profit</b>	<b>8,235</b>	<b>7,261</b>	<b>4,030</b>	<b>3,438</b>
Taxes on profit	2,034	1,915	866	947
<b>Consolidated annual surplus</b>	<b>6,201</b>	<b>5,346</b>	<b>3,164</b>	<b>2,491</b>
<b>Of the consolidated annual surplus, accounted to:</b>				
– Shareholders of Nexus AG	6,140	4,245	3,218	1,435
– Shares of non-controlling partners	61	1,101	-54	1,056
<b>Consolidated net earnings per share</b>				
<b>Weighted average (undiluted / diluted) of issued shares in circulation (in thousands)</b>	15,752 / 15,752	15,725 / 15,725	15,751 / 15,751	15,742 / 15,742
<b>Undiluted / diluted (in EUR)</b>	0.39 / 0.39	0.27 / 0.27	0.20 / 0.20	0.09 / 0.09

# Group Statement of Comprehensive Income

**FOR THE PERIOD FROM 01/01/2020 TO 30/06/2020  
AND 01/01/2019 TO 30/06/2019**

	01/01/2020–30/06/2020	01/01/2019–30/06/2019
	KEUR	KEUR
<b>Consolidated Surplus</b>	<b>6,201</b>	<b>5,346</b>
<b>Other comprehensive income</b>		
<b>Positions, which are never reclassified in profit or loss</b>		
Actuarial profits and losses	453	-3,456
Tax effects	-78	555
<b>Positions, which are reclassified in profit or loss</b>		
Currency conversions differences	-608	-335
Interest effect from IFRS 9	0	-49
<b>Other comprehensive income after taxes</b>	<b>-233</b>	<b>-3,285</b>
<b>Overall Result of the Period</b>	<b>5,968</b>	<b>2,061</b>
<b>of the overall result of the period, accounted to:</b>		
- Shareholders of Nexus AG	5,902	958
- Shares of non-controlling interests	66	1,103

# Consolidated Statement of Financial Positions

AS OF 30/06/2020 AND 31/12/2019

ASSETS	30/06/2020	31/12/2019
<b>Non-current Assets</b>	<b>KEUR</b>	<b>KEUR</b>
Goodwill	74,801	74,018
Intangible assets	35,836	38,677
Property, plant and equipment	10,433	10,794
Rights of use assets	8,806	10,791
Equity-method investments	15	15
Deferred tax assets	3,249	3,650
Other financial assets	355	355
<b>Total of non-current Assets</b>	<b>133,495</b>	<b>138,300</b>
<b>Current Assets</b>		
Inventories	352	418
Trade receivables and other receivables	24,938	25,927
Contract assets	131	640
Receivables from tax on profits	2,616	2,340
Other non-financial assets	4,885	3,049
Other financial assets	3,429	2,188
Short-term financial assets	1,602	1,671
Cash and cash equivalents	49,568	33,533
<b>Total of Short-Term assets</b>	<b>87,521</b>	<b>69,766</b>
<b>Total Assets</b>	<b>221,016</b>	<b>208,066</b>

<b>EQUITY AND LIABILITIES</b>	<b>30/06/2020</b>	<b>31/12/2019</b>
<b>Equity capital and reserves</b>	<b>KEUR</b>	<b>KEUR</b>
Subscribed capital	15,752	15,752
Capital reserves	33,141	32,987
Retained earnings	66,788	60,427
Consolidated annual surplus	6,140	10,841
Other cumulated group result	-8,904	-8,666
Own shares	54	173
<b>Equity capital attributable to shareholders of the parent company</b>	<b>112,971</b>	<b>111,514</b>
<b>Non-controlling Interests</b>	<b>3,373</b>	<b>3,621</b>
<b>Total Equity</b>	<b>116,344</b>	<b>115,135</b>
<b>Long-Term Debts</b>		
Pension obligations	17,446	17,198
Deferred tax liabilities	7,208	7,369
Other financial liabilities	10,156	13,940
Liabilities right of use	5,048	6,899
<b>Total of non-current liabilities</b>	<b>39,858</b>	<b>45,406</b>
<b>Short-Term Debts</b>		
Provisions	11,226	10,772
Financial liabilities	56	0
Trade payables	5,403	6,326
Liabilities from tax on profit	1,837	1,700
Deferred revenue	20,748	5,946
Other non-financial liabilities	4,396	4,296
Other financial liabilities	16,103	12,669
Liabilities right of use	3,814	3,966
Contract liabilities	1,231	1,850
<b>Total of current liabilities</b>	<b>64,814</b>	<b>47,525</b>
<b>Total equity and liabilities</b>	<b>221,016</b>	<b>208,066</b>

# Consolidated Cash Flow Statement

FOR THE PERIOD FROM 01/01/2020 TO 30/06/2020  
AND 01/01/2019 TO 30/06/2019

	01/01/2020-30/06/2020	01/01/2019-30/06/2019
<b>1. Cash Flow from Operating activities</b>	<b>KEUR</b>	<b>KEUR</b>
Group annual result before tax on income	8,235	7,410
Write-offs (+) / write-ups (-) on intangible assets, tangible assets and financial assets	5,999	5,927
Depreciation (+) on rights of use according to IFRS 16 leases	2,202	2,002
Other expenses not affecting payment (+) / revenue (-)	129	-1,300
Increase (-) / decrease (+) in inventories	65	-20
Gain (-) / loss (+) on disposal of fixed assets and securities	8	-21
Increase (-) / decrease (+) in receivables and other assets from operating activities	841	20,251
Increase (+) / decrease (-) of accruals insofar as not entered in other comprehensive income	-97	-2,182
Increase (+) / decrease (-) in liabilities from operating activities	10,268	-10,229 <sup>1)</sup>
Interest expense (+) / interest income (-)	-227	-283
Income tax payments (-) / Income tax received (+)	-1,342	-1,684
	<b>26,081</b>	<b>19,871</b>
<b>2. Cash Flow from Investment Activities</b>		
Payments (-) for investments in intangible and fixed assets	-2,143	-1,926
Cash proceeds (+) for sale of intangible and fixed assets	0	710
Payments (-) for the acquisition of consolidated companies less acquired cash	-541	-4,056
Payments (-) / Receipts(+) from the acquisition / disposal of short-term financial assets	0	0 <sup>1)</sup>
	<b>-2,684</b>	<b>-5,272</b>
<b>3. Cash Flow from Financing Activities</b>		
Payments (-) for the acquisition of non-controlling interests for already consolidated companies	-1,674	0
(not affecting payment) Adjustment from the application of IFRS 9	0	92
Payments (-) for the repayment of lease liabilities	-2,537	-1,961
Payments (-) of dividends	-2,835	-2,676
Payments (-) of dividends to minority shareholders	-228	0
Payments (-) for the acquisition of own shares	-59	-389
Receipts (+) from the sale of own shares	94	170
	<b>-7,239</b>	<b>-4,764</b>
Cash relevant changes in cash and cash equivalents (sum of 1 + 2 + 3)	16,158	9,835
Exchange rate changes on cash and cash equivalents	-123	-466
Cash and cash equivalents at beginning of period	<b>33,533</b>	<b>25,430</b>
Cash and cash equivalents at end of period	<b>49,568</b>	<b>34,799</b>
<b>Composition of cash and cash equivalents</b>		
Liquid funds	49,568	34,799
	<b>49,568</b>	<b>34,799</b>

# Consolidated Statement of Changes in Equity

AS OF 30/06/2020 AND 30/06/2019

	Subscribed capital	Capital reserves	Retained earnings	Net profit	Equity capital difference from currency conversation	Pension reserves	Own shares	Equity capital attributable to shareholders of the parent company	Shares of noncontrolling partners	Equity capital total	Authorized capital
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Consolidated equity as of 1 January 2019	15,752	34,166	52,182	10,921	1,131	-5,771	-759	107,622	703	108,325	2,984
Posting of consolidated surplus 2018 in the Group profit carried forward			10,921	-10,921							
Adaptation of the initial application of IFRS 9			-49					-49		-49	
Actuarial profits and losses						-3,451		-3,451	-5	-3,456	
Deffered taxes entered in other comprehensive income						554		554	1	555	
Currency differences			-1,738		1,485	-88		-341	6	-335	
Other comprehensive income after taxes			-1,787		1,485	-2,985		-3,287	2	-3,285	
Consolidated surplus 6M-2019				4,245				4,245	1,101	5,346	
Overall Result of the Period			-1,787	4,245	1,485	-2,985		958	1,103	2,061	
Dividend payment			-2,676					-2,676		-2,676	
Purchase of own shares							-389	-389		-389	
Sale and issue of own shares in the form of share-based payment		-912					1,082	170		170	
New minority interests									1,590	1,590	
Consolidated equity as of 30 June 2019	15,752	33,254	58,640	4,245	2,616	-8,756	-66	105,685	3,396	109,081	2,984

	Subscribed capital	Capital reserves	Retained earnings	Net profit	Equity capital difference from currency conversation	Pension reserves	Own shares	Equity capital attributable to shareholders of the parent company	Shares of noncontrolling partners	Equity capital total	Authorized capital
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Consolidated equity as of 1 January 2020	15,752	32,987	60,427	10,841	1,793	-10,459	173	111,514	3,621	115,135	2,984
Posting of consolidated surplus 2019 in the Group profit carried forward			10,841	-10,841							
Reclassification not affecting net income		267					-267				
Actuarial profits and losses						452		452	1	453	
Deffered taxes entered in other comprehensive income						-78		-78		-78	
Currency differences					-401	-211		-612	4	-608	
Other comprehensive income after taxes		267			-401	163	-267	-238	5	-233	
Consolidated surplus 6M-2020				6,140				6,140	61	6,201	
Overall Result of the Period		267		6,140	-401	163	-267	5,902	66	5,968	
Dividend payment			-2,835					-2,835		-2,835	
Dividend payment to minority shareholders									-228	-228	
Purchase of own shares		-113					54	-59		-59	
Sale and issue of own shares in the form of share-based payment							94	94		94	
New minority interests			-1,646					-1,646	-86	-1,732	
Consolidated equity as of 30 June 2020	15,752	33,141	66,787	6,140	1,392	-10,296	54	112,970	3,373	116,344	2,984

# Notes to the Consolidated Interim Financial Report

## 1. ACCOUNTING AND VALUATION METHOD

This interim report of the NEXUS Group of 30 June 2020 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 30 June 2020. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Notes to the Group Financial Statement 2019. The same accounting and valuation methods were used in the Group Financial Statement for the fiscal year 2019.

The report has not been audited.

The Group Financial Statement 2019 and the interim report of 30 June 2020 can be seen on the homepage in the internet at [www.nexus-ag.de](http://www.nexus-ag.de).

## 2. CONSOLIDATION GROUP

In addition to the Nexus AG as parent company, all operatively active domestic and foreign subsidiaries are included in the Group Financial Statement, for

which Nexus AG has the majority of voting rights directly or indirectly.

One affiliated company was included in the balance sheets according to the equity method.

## 3. CHANCES AND RISKS REPORT

Please refer to the explanations in the Annual Report of 31 December 2019 for information about the essential chances and risks in the development of NEXUS Group. Risks and opportunities in connection with COVID 19 – especially for the development of sales and earnings – were pointed out in this half-year report. A precise assessment of the possible effects is not possible at this time.

### List of consolidated subsidiaries, joint ventures and affiliated companies

30/06/2020

31/12/2019

Full consolidation	Country	Capital share in %	
AEGERUS SL, Sabadell <sup>1)</sup>	Spain	100.00	-
ASTRAIA Software GmbH, München <sup>2)</sup>	Germany	100.00	100.00
Creativ Software AG, Widnau <sup>3)</sup>	Switzerland	100.00	100.00
E&L medical systems GmbH, Erlangen <sup>4)</sup>	Germany	100.00	100.00
highsystem ag, Zürich <sup>5)</sup>	Switzerland	95.00	95.00
IBH Datentechnik GmbH, Kassel <sup>6)</sup>	Germany	-	100.00
ifa systems AG, Frechen	Germany	52.56	52.56
NEXUS . IT GmbH SÜDOST, Donaueschingen <sup>4)</sup>	Germany	100.00	100.00
NEXUS / ASS.TEC GmbH, Donaueschingen <sup>7)</sup>	Germany	-	100.00
NEXUS / CHILI GmbH, Dossenheim <sup>8)</sup>	Germany	83.73	83.73
NEXUS / CLOUD IT GmbH, Donaueschingen <sup>4)</sup>	Germany	100.00	100.00
nexus / cs3i S.A.S, Bellerive-sur-Allier <sup>9)</sup>	France	100.00	100.00
NEXUS / ENTERPRISE SOLUTIONS GmbH, Donaueschingen (vormals: nexus / switspot GmbH, Neckarsulm) <sup>10)</sup>	Germany	100.00	100.00

List of consolidated subsidiaries, joint ventures and affiliated companies		30/06/2020	31/12/2019
Full consolidation	Country	Capital share in %	
Nexus / IPS GmbH, Donaueschingen (vormals: Nexus Integration Solution GmbH, Donaueschingen) <sup>4)11)</sup>	Germany	100.00	100.00
NEXUS / MARABU GmbH, Berlin	Germany	100.00	100.00
NEXUS / OPTIM S.A.S, Grenoble	France	100.00	100.00
nexus / reha GmbH, Donaueschingen <sup>12)</sup>	Germany	-	100.00
Nexus Deutschland GmbH, Donaueschingen <sup>4)</sup>	Germany	100.00	100.00
NEXUS Digitale Dokumentationssysteme Projektentwicklungsges.m.b.H., Wien	Austria	100.00	100.00
NEXUS Nederland B.V., Nieuwegein	Netherlands	100.00	100.00
NEXUS POLSKA sp. z o.o., Posen <sup>13)</sup>	Poland	100.00	100.00
NEXUS Schweiz AG, Altishofen	Switzerland	100.00	100.00
NEXUS SISINF SL, Sabadell	Spain	100.00	100.00
NEXUS SWISSLAB GmbH, Berlin <sup>4)</sup>	Germany	100.00	100.00
nexus/cso GmbH, Donaueschingen <sup>4)</sup>	Germany	100.00	100.00
nexus/dis GmbH, Frankfurt am Main <sup>4)</sup>	Germany	100.00	100.00
nexus/qm GmbH, Singen Hohentwiel <sup>4)</sup>	Germany	100.00	100.00
Synergetics AG, Altishofen <sup>14)</sup>	Switzerland	-	60.00
VEGA Software GmbH, Frankfurt am Main <sup>15)</sup>	Germany	-	100.00
Equity consolidation	Country	Capital share in %	
G.I.T.S. Gesundheitswesen IT-Service GmbH Fürstenfeldbruck, Fürstenfeldbruck <sup>16)</sup>	Germany	49.00	49.00

1) Nexus AG acquired 100.00% of the shares of AEGERUS SL, Sabadell (Spain), as of 20 February 2020.

2) The share under company law is only 61.0%. There is an option agreement for the remaining 39.0% of the shares.

3) The shares are held indirectly via NEXUS Schweiz AG, Altishofen. Share under company law is only 80.0 %. There is an option agreement for the remaining 20.0% of the shares.

4) Use of the exemption rule pursuant to Section 264 (3) of the German Commercial Code

5) The shares are held indirectly via NEXUS Schweiz AG, Altishofen. Share under company law is only 80.00%. There is an option agreement for another 15.00% of the shares.

6) IBH Datentechnik GmbH, Kassel, was merged with the merger agreement of 18 November 2019 into Nexus Integration Solution GmbH, Donaueschingen, with effect from 1 January 2020.

7) NEXUS / ASS.TEC, Donaueschingen, was merged with the merger agreement of 18 November 2019 into nexus / switspot GmbH, Neckarsulm, as of 1 January 2020.

8) The share under company law is only 51.19%. There is an option agreement for the remaining 32.54 % of the shares.

9) The shares are held indirectly via NEXUS/OPTIM S.A.S, Grenoble,

10) nexus / switspot GmbH, Neckarsulm, was renamed NEXUS / ENTERPRISE SOLUTIONS GmbH, Donaueschingen, on 9 March 2020.

11) Nexus Integration Solution GmbH, Donaueschingen, was renamed Nexus / IPS GmbH, Donaueschingen, on 4 March 2020.

12) nexus / reha GmbH, Donaueschingen, was merged with the merger agreement of 18 November 2019 into nexus/cso GmbH, Donaueschingen, as of 1 January 2020.

13) Share under company law is only 77.71%. There is an option agreement for the remaining 22.29% of the shares. Nexus AG acquired a further 5.02% of the shares of the subsidiary company NEXUS POLSKA sp. z o.o., Poznan (Poland), on 23 April 2020 as well as a further 6.32% of the shares of the subsidiary company NEXUS POLSKA sp. z o.o., Poznan (Poland), on 2 June 2020 from the existing option agreement.

14) The shares are held indirectly via NEXUS Schweiz AG, Altishofen. With a share purchase agreement dated 30 April 2020, NEXUS Schweiz AG acquired the remaining 40.00% of the shares in Synergetics AG, Altishofen (Switzerland).

Synergetics AG, Altishofen (Switzerland), was merged into NEXUS Schweiz AG, Altishofen (Switzerland) as of 1 January 2020 with a merger agreement dated 16 June 2020.

15) VEGA Software GmbH, Frankfurt am Main, was merged with the merger agreement of 18 November 2019 into Nexus Deutschland GmbH, Donaueschingen, with effect from 1 January 2020.

16) G.I.T.S. Gesundheitswesen IT-Service GmbH Fürstenfeldbruck, Fürstenfeldbruck, was dissolved with effect from 1 January 2020.

#### 4. TRADE RECEIVABLES AND OTHER RECEIVABLES AS WELL AS CONTRACT ASSETS

##### Trade receivables

	30/06/2020	31/12/2019
	KEUR	KEUR
<b>Gross total</b>	30,811	30,977
<b>Risk provisioning IFRS 9</b>	975	872
<b>Sales adjustment for items still to be clarified</b>	4,898	4,178
<b>Total</b>	<b>24,938</b>	<b>25,927</b>

Long-term receivables are contained in the trade receivables with a credit term longer than one year in the amount of KEUR 127 (31 December 2019: KEUR 198).

The fair value of trade account receivables and other receivables does not differ from the book value. On 30 June 2020, trade receivables of KEUR 5,873 (31 December 2019 with a nominal value of KEUR 5,050) were impaired.

## Contract assets

	30/06/2020	31/12/2019
	KEUR	KEUR
<b>Gross total</b>	133	647
<b>Risk provisioning IFRS 9</b>	2	7
<b>Total</b>	<b>131</b>	<b>640</b>

Contract assets do not include items with a maturity greater than one year (previous year: KEUR 0).

## 5. SECURITIES

	30/06/2020		31/12/2019		30/06/2019	
	Amortized costs	Market value	Amortized costs	Market value	Amortized costs	Market value
<b>Pension funds</b>	2,014	1,602	2,014	1,671	2,014	1,633
<b>Total</b>	<b>2,014</b>	<b>1,602</b>	<b>2,014</b>	<b>1,671</b>	<b>2,014</b>	<b>1,633</b>

## 6. LIABILITIES

	30/06/2020		31/12/2019		30/06/2019	
	short-term (<1 Jahr)	long-term (>1 Jahr)	short-term (<1 Jahr)	long-term (>1 Jahr)	short-term (<1 Jahr)	long-term (>1 Jahr)
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
<b>Financial liabilities</b>	56	0	0	0	0	0
<b>Trade accounts payable</b>	5,403	0	6,326	0	6,764	0
<b>Taxes on earnings obligations</b>	1,837	0	1,700	0	1,863	0
<b>Deferred revenue</b>	20,748	0	5,946	0	17,943	0
<b>Other non-financial debts</b>	4,396	0	4,296	0	5,454	0
- Other taxes	4,396	0	4,296	0	5,454	0
<b>Contract liabilities</b>	1,231	0	1,850	0	4,540	0
<b>Other financial debts</b>	16,103	10,156	12,669	13,940	11,271	17,485
- From obligations for salary payables	7,057	0	5,933	0	3,109	0
- Other	9,046	10,156	6,736	13,940	8,162	17,485
<b>Rights of use liabilities</b>	3,814	5,048	3,966	6,899	0	0
<b>Total</b>	<b>53,588</b>	<b>15,204</b>	<b>36,753</b>	<b>20,839</b>	<b>47,835</b>	<b>17,485</b>

Conditions of the financial liabilities listed above:

- + Average down payments on orders are offset after 12 months.
- + Liabilities from deliveries and services are not interest-bearing and normally are due within 30 days.

## 7. SEGMENT REPORTING

Reporting by business segment as of June 30	Healthcare Software		Healthcare Service		Consolidation		Group	
	2020	2019	2020	2019	2020	2019	2020	2019
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
<b>Sales with customers</b>	73,307	65,673	4,352	4,035	0	0	77,659	69,708
- Services	57,916	50,737	4,133	3,927	0	0	62,049	54,664
- Licenses	11,669	12,470	208	89	0	0	11,877	12,559
- Deliveries	3,722	2,466	11	19	0	0	3,733	2,485
<b>Sales between segments</b>	33	133	1,711	1,974	-1,744	-2,107	0	0
<b>Segment sales</b>	73,340	65,806	6,063	6,009	-1,744	-2,107	77,659	69,708
<b>Operating segment result</b>	8,294	7,844	168	-356	0	0	8,462	7,488
<b>Segment assets</b>	151,043	161,882	5,857	6,112	0	0	156,900	167,994

## SEGMENTING ACCORDING BUSINESS DIVISIONS

The Group is split into business units according to products and services for the purpose of company management and has the following business segments required to file reports:

### Healthcare Software

In the business units NEXUS Germany, NEXUS Rest of Europe and NEXUS / DIS, software solutions for the healthcare system are developed and marketed in administrative and medical areas. The economic development of these business units reacts uniformly to external influences. In addition, the offered products and services, the service creation process, the customers and the sales methods are almost identical or similar. For the reasons cited, these three business units are combined in the reportable segment Healthcare Software.

### Healthcare Service

The operative segment NEXUS / CMS (Consulting & Managed Services) not allocated to the Healthcare Software reporting segment reports as an independently operating Healthcare Service segment with mandatory reporting. The companies combined under Healthcare Service are managed uniformly. Functions in the daily management of hospital IT are provided under the label NEXUS / CLOUD IT: from operations management to the support of the software applications used and user support. EDP-supported process consulting and SAP-HCM consulting, is mainly offered under the brand NEXUS / ENTERPRISE SOLUTIONS.

The balance sheet and valuation methods of both segments with mandatory reporting correspond to the same accounting methods as external reporting. Transactions between the segments are settled at customary market conditions.

## 8. SEASONAL INFLUENCES ON BUSINESS TRANSACTIONS

Within the context of the operative business of NEXUS Group, seasonal effects result due to the receipt of maintenance revenues in the first quarter of the business year (the revenue influences of the corresponding received payments are accrued over the business year) as well as the substantially higher demand and settlement of project accounts in the fourth quarter of the business year.

## RESPONSIBILITY STATEMENT

---

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 11 August 2020

Nexus AG  
The Executive Board

***nexus / ag***

Nexus AG, Irmastraße 1, 78166 Donaueschingen  
Tel. +49 771 22960-0, Fax +49 771 22960-226  
[www.nexus-ag.de](http://www.nexus-ag.de), [info@nexus-ag.de](mailto:info@nexus-ag.de)